Methods of using thiazolobenzoheterocycles

A method for treating a patient for treating Huntingdon's chorea, comprising administering to the patient an effective amount of a compound of formula (I):

• a racemate, an enantiomer, a diastereoisomer, or an inorganic or organic acid salt thereof, in which:
• R1 is a sulphur or selenium atom;
• R2 is a hydrogen atom or an alkyl radical;
• —R3—R4—R5— in the ring of formula (I) collectively is a chain having the formula:
• —CH2—CH2—CH2—, —CH(R7)—CH2—CH2—, —CH2—CH2—CH(R8)—, —CH2—CH(R9)—CH2—, —CH2—CH2—S—, —CH2—CH2—SO—, —CH2—CH2—SO2—, —CH2—CH2—Se—, —CH2—CH2—O—, —CH2—CH2—CO—, —CH2—CH2—N (R10)—, —CH2—CO—N(R10)—, —CH2—CF2—CH2—, —CH2—CF2—CH(OH)—, —CH2—CH(R13)—S—, —CH2—CH(R13)—SO—, or —CH2—CH(R13)—SO2—;
• R6 is a polyfluoroalkyl, polyfluoroalkoxy, or polyfluoroalkylthio radical;
• R7 is an alkyl, —CH2OH, —CH2—SO2-alk, or —CH2—NR11R12 radical;
• R8 is an alkyl radical, a hydroxyl, an —CH2OH, —NR11R12, —CH2—NR11R12, —S-alk, —SO-alk, —SO2-alk, thienyl, furyl, or phenyl radical, or a phenyl radical substituted with a substituent chosen from halogen atoms, alkyl radicals, and alkoxy radicals;
• R9 is an alkyl or —CH2OH radical;
• R10 is a hydrogen atom or an alkyl radical;
• R11 is a hydrogen atom, an alkyl, a —CO-alk, or —CO—CF3 radical;
• R12 is a hydrogen atom or an alkyl radical;
• or R11 and R12 form, with the nitrogen atom to which they are attached, a saturated or unsaturated 5- or 6-membered heterocycle which may optionally contain another heteroatom chosen from nitrogen, oxygen, and sulphur;
• wherein said heterocycle is unsubstituted or substituted with at least one substituent chosen from alkyl radicals, phenyl radicals, halophenyl radicals, and phenylalkyl radicals;
• R13 is an alkyl or —CH2OH radical;
• alk is an alkyl radical;
• and
• wherein, unless otherwise indicated, said alkyl and alkoxy radicals and portions thereof have from 1 to 6 straight- or branched-chain carbon atoms.

A method for treating a patient for Alzheimer's disease, comprising administering to the patient an effective amount of a compound of formula (I):

• a racemate, an enantiomer, a diastereoisomer, or an inorganic or organic acid salt thereof, in which:
• R1 is a sulphur or selenium atom;
• R2 is a hydrogen atom or an alkyl radical;
• —R3—R4—R5— in the ring of formula (I) collectively is a chain having the formula:
• —CH2—CH2—CH2—, —CH(R7)—CH2—CH2—, —CH2—CH2—CH(R8)—, —CH2—CH(R9)—CH2—, —CH2—CH2—S—, —CH2—CH2—SO—, —CH2—CH2—SO2—, —CH2—CH2—Se—, —CH2—CH2—O—, —CH2—CH2—CO—, —CH2—CH2—N(R10)—, —CH2—CO—N(R10)—, —CH2—CF2—CH2—, —CH2—CF2—CH(OH)—, —CH2—CH(R13)—S—, —CH2—CH(R13)—SO—, or —CH2—CH(R13)—SO2—;
• R6 is a polyfluoroalkyl, polyfluoroalkoxy, or polyfluoroalkylthio radical;
• R7 is an alkyl, —CH2OH, —CH2—SO2-alk, or —CH2—NR11R12 radical;
• R8 is an alkyl radical, a hydroxyl, an —CH2OH, —NR11R12, —CH2—NR11R12, —S-alk, —SO-alk, —SO2-alk, thienyl, furyl, or phenyl radical, or a phenyl radical substituted with a substituent chosen from halogen atoms, alkyl radicals, and alkoxy radicals;
• R9 is an alkyl or —CH2OH radical;
• R10 is a hydrogen atom or an alkyl radical;
• R11 is a hydrogen atom, an alkyl, a —CO-alk, or —CO—CF3 radical;
• R12 is a hydrogen atom or an alkyl radical;
• or R11 and R12 form, with the nitrogen atom to which they are attached, a saturated or unsaturated 5- or 6-membered heterocycle which may optionally contain another heteroatom chosen from nitrogen, oxygen, and sulphur;
• wherein said heterocycle is unsubstituted or substituted with at least one substituent chosen from alkyl radicals, phenyl radicals, halophenyl radicals, and phenylalkyl radicals;
• R13 is an alkyl or —CH2OH radical;
• alk is an alkyl radical;
• and
• wherein, unless otherwise indicated, said alkyl and alkoxy radicals and portions thereof have from 1 to 6 straight- or branched-chain carbon atoms.

A method for treating a patient for Parkinson's disease, comprising administering to the patient an effective amount of a compound of formula (I):

• a racemate, an enantiomer, a diastereoisomer, or an inorganic or organic acid salt thereof, in which:
• R1 is a sulphur or selenium atom;
• R2 is a hydrogen atom or an alkyl radical;
• —R3—R4—R5— in the ring of formula (I) collectively is a chain having the formula:
• —CH2—CH2—CH2—, —CH(R7)—CH2—CH2—, —CH2—CH2—CH(R8)—, —CH2—CH(R9)—CH2—, —CH2—CH2—S—, —CH2—CH2—SO—, —CH2—CH2—SO2—, —CH2—CH2—Se—, —CH2—CH2—O—, —CH2—CH2—CO—, —CH2—CH2—N(R10)—, —CH2—CO—N(R10)—, —CH2—CF2—CH2—, —CH2—CF2—CH(OH)—, —CH2—CH(R13)—S—, —CH2—CH(R13)—SO—, or —CH2—CH(R13)—SO2—;
• R6 is a polyfluoroalkyl, polyfluoroalkoxy, or polyfluoroalkylthio radical;
• R7 is an alkyl, —CH2OH, —CH2—SO2-alk, or —CH2—NR11R12 radical;
• R8 is an alkyl radical, a hydroxyl, an —CH2OH, —NR11R12, —CH2—NR11R12, —S-alk, —SO-alk, —SO2-alk, thienyl, furyl, or phenyl radical, or a phenyl radical substituted with a substituent chosen from halogen atoms, alkyl radicals, and alkoxy radicals;
• R9 is an alkyl or —CH2OH radical;
• R10 is a hydrogen atom or an alkyl radical;
• R11 is a hydrogen atom, an alkyl, a —CO-alk, or —CO—CF3 radical;
• R12 is a hydrogen atom or an alkyl radical;
• or R11 and R12 form, with the nitrogen atom to which they are attached, a saturated or unsaturated 5- or 6-membered heterocycle which may optionally contain another heteroatom chosen from nitrogen, oxygen, and sulphur;
• wherein said heterocycle is unsubstituted or substituted with at least one substituent chosen from alkyl radicals, phenyl radicals, halophenyl radicals, and phenylalkyl radicals;
• R13 is an alkyl or —CH2OH radical;
• alk is an alkyl radical;
• and
• wherein, unless otherwise indicated, said alkyl and alkoxy radicals and portions thereof have from 1 to 6 straight- or branched-chain carbon atoms.

A method for treating a patient suffering from a disorder of the nervous system which involves excess release of glutamate comprising administering to the patient an effective amount of a compound of formula (I):

• a racemate, an enantiomer, a diastereoisomer, or an inorganic or organic acid salt thereof, in which:
• R1 is a sulphur or selenium atom;
• R2 is a hydrogen atom or an alkyl radical;
• —R3—R4—R5— in the ring of formula (I) collectively is a chain having the formula:
• —CH2—CH2—CH2—, —CH(R7)—CH2—CH2—, —CH2—CH2—CH(R8)—, —CH2—CH(R9)—CH2—, —CH2—CH2—S—, —CH2—CH2—SO—, —CH2—CH2—SO2—, —CH2—CH2—Se—, —CH2—CH2—O—, —CH2—CH2—CO—, —CH2—CH2—N(R10)—, —CH2—CO—N(R10)—, —CH2—CF2—CH2—, —CH2—CF2—CH(OH)—, —CH2—CH(R13)—S—, —CH2—CH(R13)—SO—, or —CH2—CH(R13)—SO2—;
• R6 is a polyfluoroalkyl, polyfluoroalkoxy, or polyfluoroalkylthio radical;
• R7 is an alkyl, —CH2OH, —CH2—SO2-alk, or —CH2—NR11R12 radical;
• R8 is an alkyl radical, a hydroxyl, an —CH2OH, —NR11R12, —CH2—NR11R12, —S-alk, —SO-alk, —SO2-alk, thienyl, furyl, or phenyl radical, or a phenyl radical substituted with a substituent chosen from halogen atoms, alkyl radicals, and alkoxy radicals;
• R9 is an alkyl or —CH2OH radical;
• R10 is a hydrogen atom or an alkyl radical;
• R11 is a hydrogen atom, an alkyl, a —CO*alk, or —CO—CF3 radical;
• R12 is a hydrogen atom or an alkyl radical;
• or R11 and R12 form, with the nitrogen atom to which they are attached, a saturated or unsaturated 5- or 6-membered heterocycle which may optionally contain another heteroatom chosen from nitrogen, oxygen, and sulphur;
• wherein said heterocycle is unsubstituted or substituted with at least one substituent chosen from alkyl radicals, phenyl radicals, halophenyl radicals, and phenylalkyl radicals;
• R13 is an alkyl or —CH2OH radical;
• alk is an alkyl radical;
• and
• wherein, unless otherwise indicated, said alkyl and alkoxy radicals and portions thereof have from 1 to 6 straight- or branched-chain carbon atoms.